Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
View Patent ↗The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
1. A compound of formula I:
wherein
B is C(R4) or N;
R1 is H, halogen, (C1-C8) alkyl, (C0-C4) alkylene-O—(C0-C4) alkylene-H, (C0-C2) alkylene-O—(C0-C2) alkylene-(C3-C6) cycloalkyl, SCH3, or CN, wherein the alkyl and alkylene are unsubstituted or mono, bi- or trisubstituted by F;
R2, R3, and R4 are independently
H, halogen, (C1-C8) alkyl, (C0-C4) alkylene-O—(C0-C4) alkylene-H, SCH3, or CN, wherein the alkyl and alkylene are unsubstituted or mono, bi- or trisubstituted by F;
X is O, S, S(O), S(O)2, O-CH2, S—CH2, CH2-O, or CH2-S;
one of U and V is N, and the other is S or O;
W is a bond, (C1-C8) alkylene, (C2-C8) alkenylene, (C0-C6) alkylene-(C3-C6) cycloalkylene, or (C3-C6) cycloalkylene-(C1-C6) alkylene, wherein the alkylene, alkenylene and cycloalkylene are unsubstituted or mono-, di- or trisubstituted by OH or F;
Y is S, S(O), S(O)2, or N(R6),
R5 is H, (C1-C8) alkyl, (C0-C4) alkylene-(C3-C13) cycloalkyl, (C0-C4) alkylene-(C6-C14) aryl, (C2-C8) alkenyl, (C0-C4) alkylene-(C3-C15) heterocycloalkyl, (C0-C4) alkylene-(C3-C15) heterocycloalkenyl, (C0-C4) alkylene-(C5-C15) heteroaryl, (C0-C4) alkylene-CO—(C1-C4) alkyl, (C0-C4) alkylene-CO—(C0-C4) alkylene-(C3-C13)cycloalkyl, (C0-C4) alkylene-CO—(C0-C4) alkylene-(C6-C10)aryl, (C0-C4) alkylene-CO—(C0-C4) alkylene-(C3-C15) heterocycloalkyl, (C0-C4) alkylene-CO—(C0-C4) alkylene-(C3-C15) heterocycloalkenyl, (C0-C4) alkylene-CO—(C0-C4) alkylene-(C5-C15) heteroaryl, SO2-(C1-C4) alkyl, SO2-(C0-C4) alkylene-(C3-C13)cycloalkyl, SO2-(C0-C4) alkylene-(C6-C10) aryl, SO2-(C0-C4) alkylene-(C3-C15) heterocycloalkyl, SO2-(C0-C4) alkylene-(C3-C15) heterocycloalkenyl, SO2-(C0-C4) alkylene-(C5-C15) heteroaryl, CO-O—(C0-C4) alkylene-(C6-C10) aryl, CO—O—(C1-C4) alkyl, CO—O—(C0-C4) alkylene-(C3-C13) cycloalkyl, CO—O—(C0-C4) alkylene-(C3-C15)heterocycloalkyl, CO—O—(C0-C4) alkylene-(C3-Cl5)heterocycloalkenyl, CO—O—(C0-C4) alkylene-(C5-C15)heteroaryl, CO—N((C0-C4) alkylene-H)-(C0-C4) alkylene-(C6-C10) aryl, CO—N((C0-C4) alkylene-H)-(C0-C4) alkylene-H, CO—N((C0-C4) alkylene-H)-(C0-C4) alkylene-(C3-C13)cycloalkyl, CO—N((C0-C4) alkylene-H)-(C0-C4) alkylene-(C3-C15) heterocycloalkyl, CO—N((C0-C4) alkylene-H)-(C0-C4) alkylene-(C3-C15) heterocycloalkenyl, CO—N((C0-C4) alkylene-H)-(C0-C4) alkylene-(C5-C15) heteroaryl, SO2-N((C0-C4)alkylene-H)-(C0-C4) alkylene-(C6-C10)aryl, SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-H, SO2-N((C0-C4) alkylene-H)-(C0-C4)alkylene-(C3-C13)cycloalkyl, SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycloalkyl, SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycloalkenyl, or SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C5-C15)heteroaryl, wherein the alkyl and alkylene are unsubstituted or mono-, di- or trisubstituted by F, S-(C1-C4) alkyl, SO-(C1-C4) alkyl, SO2-(C1-C4) alkyl, CO—N((C0-C4)alkylene-H)-(C0-C4) alkylene-H, N((C0-C4) alkylene-H)-(C0-C4) alkylene-H, CO-0(C 1-C4) alkyl, (C1-C4) alkyl or O—(C0-C4) alkylene-H, and wherein the cycloalkyl, aryl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are unsubstituted or mono-, di-or trisubstituted by F, Cl, Br, CF3, (C1-C4) alkyl or (C0-C4)-alkylen-O—(C0-C4)alkylene-H,
provided that:
when Y is S, S(O) or S(O)2, then R5 is not SO2-(C1-C4)alkyl, SO2-(C0-C4)alkylene-(C3-C13)cycloalkyl, SO2-(C0-C4)alkylene-(C6C10)aryl, SO2-(C0-C4)alkylene-(C3-C15)heterocycloalkyl, SO2-(C0-C4)alkylene-(C3-Cl5)heterocycloalkenyl, SO2-(C0-C4)alkylene-(C5-C15)heteroaryl, SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C6-C10)aryl, SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-H, SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C13)cycloalkyl, SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycloalkyl, SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycloalkenyl, or SO2-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C5-C15)heteroaryl;
R6 is H, (C1-C8)alkyl, (C2-C8)alkenyl, or (C0-C4)alkylene-(C3-C6)cycloalkyl, wherein the alkyl and alkenyl are unsubstituted or mono-, di- or trisubstituted by F or O—(C0-C4)-alkylene-H; or
When Y is N(R6), R5 and R6 together with the nitrogen atom to which they are bonded may form a (C3-C15)-heterocycloalkyl, a (C3-C15)-heterocycloalkenyl or a (C5-C15)-heteroaryl, each of which can contain additionally 1 to 3 heteroatoms selected from N, O, and S, wherein the heteroatoms can be oxidized, and each of which is unsubstituted or mono-, di- or trisubstituted by halogen, CN, CF3, (C1-C4) alkyl, (C0-C4) alkylene-(C3-C6) cycloalkyl, (C0-C4) alkylene-O—(C0-C4) alkylene-H, (C0-C4) alkylene-O—(C0-C4) alkylene-(C3-C6) cycloalkyl, (C0-C4) alkylene-O—(C0-C4) alkylene-(C6-C10)aryl, (C0-C4) alkylene-O—(C0-C4)alkylene-(C3-C15) heterocycloalkyl, (C0-C4)alkylene-O—(C0-C4) alkylene-(C3-C15) heterocycloalkenyl, (C0-C4)alkylene-O—(C0-C4)alkylene-(C5-C15) heteroaryl, (C0-C4) alkylene-S-(C1-C4) alkyl, (C0-C4) alkylene-SO—(C1-C4) alkyl, (C0-C4) alkylene-SO2-(C1-C4) alkyl, (C0-C4) alkylene-O—(C1-C4) alkyl, (C0-C4) alkylene-CO—(C6-C10)aryl, (C0-C4) alkylene-O-(C3-C15)heterocycloalkyl, (C0-C4) alkylene-O—(C3-C15)heterocycloalkenyl, (C0-C4) alkylene-O—(C5-C15)heteroaryl, (C0-C4) alkylene-CO—N((C0-C4) alkylene-H)-(C0-C4) alkylene-H, (C0-C4)alkylene-CO—N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C6)cycloalkyl, (C0-C4)alkylene-CO—N ((C0-C4)alkylene-H)-(C0-C4)alkylene-(C6-C10)aryl, (C0-C4)alkylene-CO—N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycloalkyl, (C0-C4)alkylene-CO—N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycloalkenyl, (C0-C4)alkylene-CO—N ((C0-C4)alkylene-H)-(C0-C4)alkylene-(C5-C15)heteroaryl, (C0-C4) alkylene-N ((C0-C4) alkylene-H)—CO—(C1-C4) alkyl, (C0-C4) alkylene-N((C0-C4) alkylene-H)—CO—(C0-C4)alkylene-(C3-C6) cycloalkyl, (C0-C4) alkylene-N((C0-C4) alkylene-H)—CO—(C0-C4) alkylene-(C6-C10)aryl, (C0-C4)alkylene-N((C0-C4) alkylene-H)—CO—(C0-C4) alkylene-(C3-C15)heterocycloalkyl, (C0-C4)alkylene-N((C0-C4) alkylene-H)—CO—(C0-C4)alkylene-(C3-C15)heterocycloalkenyl, (C0-C4)alkylene-N((C0-C4) alkylene-H)—CO—(C0-C4)alkylene-(C5-C15)heteroaryl, (C0-C4) alkylene-(C6-C14) aryl and (C0-C4) alkylene-(C3-C15) heterocycloalkyl, (C0-C4) alkylene-(C3-C15) heterocycloalkenyl, or (C0-C4) alkylene-(C5-C15) heteroaryl, wherein the heteroaryl, heterocycloalkyl and heterocycloalkenyl can be mono- or disubstituted by oxo, and wherein the alkyl can be unsubstituted or mono-, di- or trisubstituted by F;
Z is a bond, (C1-C8) alkylene, (C2-C8) alkenylene, (C2-C8) alkylidene, or (C1-C6) alkylene-O—(C1-C6) alkylene; and
R7 and R8 are independently H, halogen, (Cl-C8) alkyl, (C0-C4) alkylene-O—(C0-C4) alkylene-H, SCF3, SF5, S(O)2CF3, (C0-C4) alkylene-O—(C6-C12) aryl, (C0-C4) alkylene (C6-C12) aryl, or NO2, wherein the alkyl and alkylene are unsubstituted or mono-, di- or trisubstituted by F, and the aryl is unsubstituted or mono-, di- or trisubstituted by halogen, (C1-C4) alkyl or O—(C1-C4) alkyl;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
2. The compound according to claim 1 , wherein:
R4 is H, (C1-C8) alkyl, or (C0-C4) alkylene-O—(C0-C4) alkylene-H, wherein the alkyl and alkylene are unsubstituted or mono, di- or trisubstituted by F;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
3. The compound according to claim 1 , wherein
B is C(R4); and
R4 is H;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
4. The compound according to claim 1 , wherein
R1 is halogen, (C1-C4) alkyl, (C0-C4) alkylene-O—(C0-C2) alkylene-H, or O—(C0-C2) alkylene-(C3-C6) cycloalkyl, wherein the alkyl and alkylene are unsubstituted or mono, di- or trisubstituted by F;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
5. The compound according to claim 1 , wherein
W is (Cl-C3) alkylene;
Y is N(R6); and
R5 and R6 together with the nitrogen atom to which they are attached form a (C3-C7)-heterocycloalkyl, a (C4-C7)-heterocycloalkenyl or a (C5-C8)-heteroaryl, each of which can contain additionally 1 to 2 heteroatoms selected from N, O and S, and each of which is unsubstituted or mono- or disubstituted by F, CF3, (C1-C3) alkyl, (C0-C3) alkylene-O—(C0-C3) alkylene-H, SO2-(C1-C3) alkyl, CO—(C1-C3) alkyl, CO—NH2, NH—CO—(C1-C3) alkyl, phenyl, (C5-C6) heteroaryl, (C3-C7) heterocycloalkyl or (C4-C7) heterocycloalkenyl, wherein the heterocycloalkyl, heterocycloalkenyl and heteroaryl can be mono- or disubstituted by oxo;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
6. The compound according to claim 1 , wherein
W is (C1-C3) alkylene;
Y is N(R6),
R5 is H, (C1-C4) alkyl, (C0-C3) alkylene-(C3-C7) cycloalkyl, (C0-C3) alkylene-phenyl, (C0-C3) alkylene-(C3-C7) heterocycloalkyl, (C0-C4) alkylene-(C4-C7) heterocycloalkenyl, (C0-C3) alkylene-(C5-C6) heteroaryl, CO—(C0-C3) alkyl, or CO—O-phenyl, wherein the alkyl and alkylene can be mono-, di- or trisubstituted by F, S—(C1-C3) alkyl, SO—(C1-C3) alkyl, SO2-(C1-C3) alkyl, N((C0-C3) alkylene-H)-(C0-C3) alkylene-H, CO—O(C1-C3) alkyl or O—(C0-C3) alkylene-H, wherein the cycloalkyl, phenyl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are mono-, di- or trisubstituted by F or (C0-C4)-alkylen-O(C0-C4) alkylene-H, and
R6 is H, (C1-C3) alkyl or (C0-C3) alkylene-(C3-C6) cycloalkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted by O—(C0-C4)-alkylene-H; or
Y is S, S(O) or S(O)2, and
R5 is (C1-C3) alkyl or (C0-C3) alkylene-(C3-C6) cycloalkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted by F;
Z is —CH2-, —CH2-CH2-, —CH2-O—CH2-, or —CH═CH—;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
7. The compound according to claim 1 , wherein
V is N; and
U is O or S;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
8. The compound according to claim 1 , wherein X is O or O—CH2;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
9. The compound according to claim 1 , wherein
W is a bond or —CH2-;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
10. The compound according to claim 1 , wherein
R7 is at para-position;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
11. The compound according to claim 1 , wherein
R8 is H;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
12. The compound according to claim 1 , wherein
R1 is halogen, (C1-C4) alkyl, (C0-C4) alkylene-O—(C0-C2) alkylene-H, or O—(C0-C2) alkylene-(C3-C6) cycloalkyl, wherein the alkyl and alkylene are unsubstituted or mono, di- or trisubstituted by F;
W is (C1-C3) alkylene;
Y is N(R6), and
R5 and R6 together with the nitrogen atom to which they are attached form a (C3-C7)-heterocycloalkyl, a (C4-C7)-heterocycloalkenyl or a (C5-C8)-heteroaryl, each of which can contain additionally 1 to 2 heteroatoms selected from N, O and S, and each of which is unsubstituted or mono- or disubstituted by F, CF3, (C1-C3) alkyl, (C0-C3) alkylene-O—(C0-C3) alkylene-H, SO2-(C1-C3) alkyl, CO—(C1-C3) alkyl, CO—NH2, NH—CO—(C1-C3) alkyl, phenyl, (C5-C6) heteroaryl, (C3-C7) heterocycloalkyl or (C4-C7) heterocycloalkenyl, wherein the heterocycloalkyl, heterocycloalkenyl and heteroaryl can be mono- or disubstituted by oxo; or
Y is N(R6),
R5 is H, (C1-C4) alkyl, (C0-C3) alkylene-(C3-C7) cycloalkyl, (C0-C3) alkylene-phenyl, (C0-C3) alkylene-(C3-C7) heterocycloalkyl, (C0-C4) alkylene-(C4-C7) heterocycloalkenyl, (C0-C3) alkylene-(C5-C6) heteroaryl, CO—(C0-C3) alkyl, or CO—O-phenyl, wherein the alkyl and alkylene can be mono-, di- or trisubstituted by F, S—(C1-C3) alkyl, SO—(C1-C3) alkyl, SO2-(C1-C3) alkyl, N((C0-C3) alkylene-H)-(C0-C3) alkylene-H, CO-O(C1-C3) alkyl or O —(C0-C3) alkylene-H and wherein the cycloalkyl, phenyl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are mono-, di- or trisubstituted by F or (C0-C4)-alkylen-O—(C0-C4) alkylene-H, and
R6 is H, (C1-C3) alkyl or (C0-C3) alkylene-(C3-C6) cycloalkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted by O—(C0-C4)-alkylene-H; or
Y is S, S(O), or S(O)2, and
R5 is (C1-C3) alkyl or (C0-C3) alkylene-(C3-C6) cycloalkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted by F;
and
Z is —CH2-, —CH2-CH2-, —CH2-O—CH2-, —CH═CH—;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
13. The compound according to claim 1 , wherein
B is C(R4);
R4 is H;
R1 is F, Cl, (C1-C4) alkyl, (C0-C4) alkylene-O—(C1-C4) alkylene-H, or (C0-C2) alkylene-O—(C0-C2) alkylene-(C3-C6) cycloalkyl, wherein the alkyl and alkylene are unsubstituted or mono, bi- or trisubstituted by F;
R2 is H;
R3 is H, F or Br;
R4 is H;
X is O or O—CH2;
U is S or O, and
V is N; or
U is N, and
V is O;
W is a bond, or (C1-C4) alkylene;
Y is N(R6), and
R5 is (C1-C8) alkyl, (C0-C4) alkylene-(C3-C13) cycloalkyl, (C0-C4) alkylene-(C6-C12) aryl, (C0-C4) alkylene-(C3-C15) heterocycloalkyl CO—(C0-C4) alkyl, or CO—O—(C6-C10) aryl, wherein the alkyl and alkylene can be mono-, di- or trisubstituted by S—(C1-C4) alkyl, SO—(C1-C4) alkyl, N((C0-C4) alkylene-H)-(C0-C4) alkylene-H or O—(C0-C4) alkylene-H, and wherein the aryl and heterocycloalkyl are mono-, di- or trisubstituted by F or (C0-C4)-alkylene-O—(C0-C4) alkylene-H,
R6 is H, (C1-C8) alkyl or (C0-C4) alkylene-(C3-C6) cycloalkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted by O—(C0-C4)-alkylene-H, or
R5 and R6 together with the nitrogen atom to which they are attached can form a (C3-C8)-heterocycloalkyl, or a (C3-C10)-heterocycloalkenyl, each of which can contain additionally 1 to 3 heteroatoms selected from N, O and S, and each of which is unsubstituted or mono-, di- or trisubstituted by F, CF3, (C1-C4) alkyl, (C0-C4) alkylene-O—(C0-C4) alkylene-H, SO2-(C1-C4) alkyl, or CO—(C1-C4) alkyl, wherein the heterocycloalkyl can be mono- or disubstituted by oxo; or
Y is S, S(O), or S(O)2, and
R5 is (C1-C3) alkyl;
Z is a bond, (C1-C2) alkylene, (C2) alkenylene, (C1-C2) alkylene-O—(C1-C2) alkylene;
R7 is H, O—(C1-C4) alkyl, or CF3; and
R8 is H;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
14. The compound according to claim 1 , wherein:
R1 is halogen, (C1-C4) alkyl, OH, or O—(C1-C3) alkyl, wherein the alkyl is unsubstituted or mono, di- or trisubstituted by F;
R2 is H;
R3 is H or F;
B is C(R4) or N;
R4 is H;
X is O;
one of U and V is N, and the other is S or O;
W is (C1-C3) alkylene;
Y is N(R6), and R5 and R6 together with the nitrogen atom to which they are attached form a (C3-C7)-heterocycloalkyl, a (C4-C7)-heterocycloalkenyl or a (C5-C8)-heteroaryl, each of which can contain additionally 1 to 2 heteroatoms selected from N, O and S, and each of which is unsubstituted or mono- or disubstituted by F, CF3, (C1-C3) alkyl, (C0-C3) alkylene-O—(C0-C3) alkylene-H, SO2-(C1-C3) alkyl, CO—(C1-C3) alkyl, CO—NH2, NH—O—(C1-C3) alkyl, phenyl, (C5-C6) heteroaryl, (C3-C7) heterocycloalkyl or (C4-C7) heterocycloalkenyl, wherein the heterocycloalkyl, heterocycloalkenyl and heteroaryl can be mono- or disubstituted by oxo; or
Y is N(R6),
R5 is H, (C1-C4) alkyl, (C0-C3) alkylene-(C3-C7) cycloalkyl, (C0-C3) alkylene-phenyl, (C0-C3) alkylene-(C3-C7) heterocycloalkyl, (C0-C4) alkylene-(C4-C7) heterocycloalkenyl, (C0-C3) alkylene-(C5-C6) heteroaryl, CO—(C0-C3) alkyl, or CO—O-phenyl, wherein the alkyl and alkylene can be mono-, di- or trisubstituted by F, S—(C1-C3) alkyl, SO—(C1-C3) alkyl, SO2-(C1-C3) alkyl, N((C0-C3) alkylene-H)-(C0-C3) alkylene-H, CO—O(C1-C3) alkyl or O—(C0-C3) alkylene-H, and wherein the cycloalkyl, phenyl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are mono-, di- or trisubstituted by F or (C0-C4)-alkylen-O—(C0-C4) alkylene-H, and
R6 is H, (C1-C3) alkyl or (C0-C3) alkylene-(C3-C6) cycloalkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted by O—(C0-C4)-alkylene-H; or
Y is S, S(O), or S(O)2, and
R5 is (C1-C3) alkyl or (C0-C3) alkylene-(C3-C6) cycloalkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted by F;
Z is a bond, (C1-C2) alkylene, (C2) alkenylene, (C1-C2) alkylene-O—(C1-C2) alkylene;
R7 is H, halogen, (C1-C3) alkyl, or O—(C1-C3) alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted by F; and
R8 is H;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof
15. The compound according to claim 1 , wherein:
R1 is F, OH, OCH3, OCHF2, or OCH2CF3;
R2 is H;
R3 is H or F;
B is C(R4) or N;
R4 is H;
X is O;
one of U and V is N, and the other is S or O;
W is CH2, or CH2CH2CH2;
Y is N(R6), and
R5 and R6 together with the nitrogen atom to which they are bonded (Y ═N(R6)) form piperidine, pyrrolidine, azetidine, azepine, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S-dioxide, piperazine, piperazinone, or iso-indoline, each of which is unsubstituted or mono- or disubstituted by F, CF3, (C1-C3) alkyl, O—(C1-C3) alkyl, OH, CH2OH, SO2CH3, COCH3, or phenyl; or
Y is S, S(O), or S(O)2, and
R5 is CH3;
Z is a bond;
R7 is CF3; and
R8 is H;
or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
16. A pharmaceutical composition comprising the compound according to claim 1 , or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.
17. The pharmaceutical composition according to claim 16 , further comprising an additional active substance, wherein the additional active substance has a favorable effect on metabolic disturbance or a disorder that may be associated therewith.
18. The pharmaceutical composition according to claim 16 , further comprising an antidiabetics.
19. The pharmaceutical composition according to claim 16 , further comprising a lipid lowering agent.
20. A method for treating a disorder of fatty acid metabolism, glucose utilization disorder, a disorder in which insulin resistance is involved, diabetes mellitus or a squeal associated therewith, dyslipidemia or a squeal associated therewith, a condition which is associated with metabolic syndrome, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 1 , or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof.
21. A process for preparing a pharmaceutical composition comprising the compound according to claim 1 , or a stereoisomer, enantiomer or tautomer thereof, or a physiologically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient, which comprises mixing the compound according to claim 1 , or the stereoisomer, enantiomer or tautomer thereof, or the physiologically acceptable salt thereof, with the pharmaceutically acceptable carrier or excipient and bringing this mixture into a form suitable for administration.